Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG-2401
- Development stage
- Preclinical
- Lead developer
- AHN-GOOK PHARMACEUTICAL
- Modality
- Small Molecules
01
Overview
AG-2401 is an investigational 'Improved New Drug' (IMD) being developed by Ahn-Gook Pharmaceuticals for the treatment of endocrine diseases, with a specific focus on diabetes. Currently in the research stage, AG-2401 is part of the company's pipeline of value-added medicines designed to improve upon existing therapeutic options through optimized formulations, new delivery methods, or fixed-dose combinations. In the South Korean regulatory context, an IMD (개량신약) must demonstrate a clear improvement in safety, efficacy, or convenience over the original reference drug. As of now, the specific molecular targets and active pharmaceutical ingredients of AG-2401 have not been publicly disclosed.
Beyond the preview
Go deeper on AG-2401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AG-2401.